perturbation-biology
(2)
Zafrens
Zafrens is a San Diego biotechnology company building an ultra-high-throughput single-cell platform that isolates, images, runs assays on, and sequences millions of individual cells per day. Its Z-Screen technology swaps the conventional 96-well plate for a credit-card-sized plastic chip holding 50,000 to 200,000 microwells, each with integrated imaging and multi-omic sequencing. By linking perturbation to genotype, phenotype and function at single-cell resolution, Zafrens compresses multiple stages of drug discovery into a single benchtop experiment - a 500x to 2,000x jump in the number of experiments a scientist can run at one timepoint.
Swamy Vijayan
Swamy Vijayan is the CEO and cofounder of Zafrens, a San Diego biotech reinventing drug discovery by shrinking a 96-well plate down to 200,000 microwells that image and sequence single cells at once. A physicist by training who admits he was driven less by a love of biology than by dissatisfaction with theoretical physics, he is a serial founder whose previous company Omniome sold to Pacific Biosciences for up to $800 million. His stated goal is not a quick exit but a foundation for smart people to do important things for the next 100 years.